5
IRUS Total
Downloads

Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?

File Description SizeFormat 
56197-PB3-7894-R3.pdfPublished version564.32 kBAdobe PDFView/Open
Title: Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
Authors: Peng, L
Stebbing, J
Liang, F
Xia, Y
Item Type: Journal Article
Issue Date: 30-Aug-2021
Date of Acceptance: 30-Aug-2021
URI: http://hdl.handle.net/10044/1/92120
DOI: 10.21037/tlcr-21-650
ISSN: 2218-6751
Publisher: AME Publishing
Start Page: 3858
End Page: 3860
Journal / Book Title: Translational Lung Cancer Research
Volume: 10
Issue: 9
Copyright Statement: © Translational Lung Cancer Research. All rights reserved. This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
Sponsor/Funder: Imperial College Healthcare NHS Trust- BRC Funding
National Institute for Health Research
Funder's Grant Number: RDB01 79560
NIHR-RP-011-053
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Respiratory System
1ST-LINE TREATMENT
PEMBROLIZUMAB
CHEMOTHERAPY
Science & Technology
Life Sciences & Biomedicine
Oncology
Respiratory System
1ST-LINE TREATMENT
PEMBROLIZUMAB
CHEMOTHERAPY
1103 Clinical Sciences
1112 Oncology and Carcinogenesis
Publication Status: Published
Online Publication Date: 2021-09
Appears in Collections:Department of Surgery and Cancer



This item is licensed under a Creative Commons License Creative Commons